GSK’s new CEO eyes more dealmaking, intense pipeline inspectionnews2026-02-04T15:01:47+00:00February 4th, 2026|Endpoints News|
Novartis says generics to erode $4B from 2026 salesnews2026-02-04T12:44:26+00:00February 4th, 2026|Endpoints News|
Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cutsnews2026-02-04T10:55:33+00:00February 4th, 2026|Endpoints News|
Ultragenyx unwraps data that may be central to its gene therapy resubmissionnews2026-02-03T13:00:48+00:00February 3rd, 2026|Endpoints News|
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earningsnews2026-02-03T12:51:41+00:00February 3rd, 2026|Endpoints News|
Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?news2026-02-03T12:30:48+00:00February 3rd, 2026|Endpoints News|
New CagriSema data show improvement over semaglutidenews2026-02-02T19:16:29+00:00February 2nd, 2026|Endpoints News|
GSK returns rights to Wave’s RNA editing program for AATDnews2026-02-02T16:06:46+00:00February 2nd, 2026|Endpoints News|
Sanofi’s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry diseasenews2026-02-02T12:12:25+00:00February 2nd, 2026|Endpoints News|
Bitterroot reverts to preclinical biotech in CD47 as CEO leavesnews2026-01-30T17:30:44+00:00January 30th, 2026|Endpoints News|
